Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Introduces Fiscal Year 2021 GuidanceGlobeNewsWire • 03/16/21
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and MarchGlobeNewsWire • 02/09/21
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 16, 2021GlobeNewsWire • 02/08/21
Earnings Estimates Rising for ORGANOGENESIS (ORGO): Will It Gain?Zacks Investment Research • 01/20/21
Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee OsteoarthritisGlobeNewsWire • 01/14/21
Organogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020GlobeNewsWire • 01/13/21
Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the KneeGlobeNewsWire • 01/11/21
Organogenesis: Revenue Generating Regenerative Medicines Company Looking InterestingSeeking Alpha • 11/20/20
Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common StockGlobeNewsWire • 11/13/20
Organogenesis Holdings Inc. Announces Proposed Public Offering of Class A Common StockGlobeNewsWire • 11/10/20
Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/10/20
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial ResultsGlobeNewsWire • 11/09/20
Latest Wound Care Research from Organogenesis Highlighted at SAWC Fall 2020 Virtual MeetingGlobeNewsWire • 11/02/20